SFM
BMRN icon

Systematic Financial Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Systematic Financial Management’s Portfolio BMRN Stock Details BMRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.6M Buy
290,249
+34,895
+14% +$1.91M 0.33% 119
2026
Q1 		$14.4M Buy
255,354
+954
+0.4% +$55.6K 0.33% 117
2025
Q4 		$15.1M Buy
254,400
+243,665
+2,270% +$13.3M 0.36% 110
2025
Q3 		$581K Buy
+10,735
New +$614K 0.01% 217

Other funds holding BMRN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Systematic Financial Management's BMRN Position: Q2 2026 in Review

Systematic Financial Management increased its BioMarin Pharmaceuticals (BMRN) stake by 14% in Q2 2026, buying an estimated $1.91M and bringing the position to 290,249 shares worth $16.6M. The position accounts for 0.33% of the portfolio, ranked #119.

Systematic Financial Management first reported a position in BMRN in Q3 2025 and has held it in 4 quarters since. 564 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

  • Systematic Financial Management held 290,249 shares of BioMarin Pharmaceuticals worth $16.6M as of Q2 2026.
  • Systematic Financial Management bought 34,895 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $1.91M.
  • BioMarin Pharmaceuticals made up 0.33% of Systematic Financial Management's portfolio in Q2 2026, its #119 holding.
  • Systematic Financial Management first reported a position in BioMarin Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 564 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Systematic Financial Management's 13F filing for Q2 2026, filed 14 Aug 2026.